这项研究在所有达到持续病毒学反应（SVR）的患者人群中，前瞻性地观察所有恶性肿瘤的发病率和所有患者的预后，捕获率为100%。从2013年7月至2021年12月，进行了651例SVR病例的前瞻性研究。主要终点是所有恶性肿瘤的发生率，次要终点是总体生存率。使用人年法计算随访期间的癌症发生率，分析危险因素。此外，还使用性别和年龄匹配的标准化死亡率比（SMR）来比较普通人群与研究人群。总体中位随访时间为5.44年。在随访期间，99名患者中发生了107个恶性肿瘤。所有恶性肿瘤的发病率为3.94/100人年。1年累积发病率为3.6％，3年为11.1％，5年为17.9％，并且几乎呈线性上升趋势。肝癌和非肝癌的发病率分别为1.94/100患者年和1.81％/100患者年。1年、3年和5年的生存率分别为99.3％、96.5％和94.4％。将此寿命预期与日本人口的标准化死亡率比较，证明两者不劣。发现其他器官的恶性肿瘤的发生率与肝细胞癌（HCC）同样频繁。因此，达到SVR的患者的随访应该不仅关注HCC，还应该关注其他器官的恶性肿瘤，并且终身随访可能会延长之前短暂的寿命期望。 ©2023年。亚太肝病研究协会。

This study prospectively observed the incidence of all malignancies and the prognosis of all patients in a population of patients who achieved Sustained Virological Response (SVR) with a 100% capture rate.A prospective study of 651 SVR cases was conducted from July 2013 to December 2021. The primary endpoint was the occurrence of all malignancies, and the secondary endpoint was overall survival. The cancer incidence during the follow-up period was calculated using the man-year method, and risk factors were analyzed. In addition, sex- and age-matched standardized mortality ratio (SMR) was used to compare the general population with the study population.The overall median follow-up was 5.44 years. 107 malignancies occurred in 99 patients during the follow-up. The incidence of all malignancies was 3.94/100 person-years. The cumulative incidence was 3.6% at 1 year, 11.1% at 3 years, and 17.9% at 5 years, and continued to increase almost linearly. The incidence of liver cancer and non-liver cancer was 1.94/100 patient-years vs. 1.81%/100 patient-years. The 1-year, 3-year, and 5-year survival rates were 99.3%, 96.5%, and 94.4%, respectively. This life expectancy was compared to the standardized mortality ratio of the Japanese population, which proved non-inferior.It was found that malignancies of other organs occur as frequently as hepatocellular carcinoma (HCC). Therefore, follow-up of patients who have achieved SVR should focus not only on HCC but also on malignant tumors of other organs, and lifelong follow could contribute prolonged life expectancy for the previously short-lived.© 2023. Asian Pacific Association for the Study of the Liver.